150338-90-2 (N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-acetamide,N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-acetamide)

C2 L-erythro Ceramide (d18:1/2:0);Acetamide, N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-;Acetyl-L-erythro-sphingosine;MFCD00153903;C2 Ceramide (d18:1/2:0);N-[(E,2R,3S)-1,3-dihydroxyoctadec-4-en-2-yl]acetamide;150338-90-2;CHEMBL1221816;N-Acetyl-D-sphingosine;Acetyl ceramide;(2S,3R,4E)-2-(Acetylamino)-4-octadecene-1,3-diol;N-acetyl-d-sphin-gosine;N-Acetyl-D-sphingosine, >=97% (TLC), powder;N-((2R,3S,E)-1,3-dihydroxyoctadec-4-en-2-yl)acetamide;N-[(1R,2S,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]-acetamide;N-Acetyl-D-sphingosine, >=98.0% (TLC);

BLTCBVOJNNKFKC-HEQKZDDYSA-N

1S/C20H39NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(24)19(17-22)21-18(2)23/h15-16,19-20,22,24H,3-14,17H2,1-2H3,(H,21,23)/b16-15+/t19-,20+/m1/s1

C(N[C@H](CO)[C@@H](O)/C=C/CCCCCCCCCCCCC)(=O)C